OEM News

CES 2025: APNEAL Unveils the World’s First AI-Powered App to Detect Sleep Apnea

The app is backed by 8 years of research and provides clinical-grade accuracy with a 90% correlation rate with polysomnography.

Author Image

By: Rachel Klemovitch

Assistant Editor

APNEAL has unveiled the first-ever medical device technology that enables advanced sleep examinations at home using a smartphone. This AI-powered app transforms ordinary smartphones into accessible diagnostic tools, eliminating the need for sleep clinics or complex equipment for most patients. 

The user attaches their smartphone to their chest with an adhesive strip (available at pharmacies) and activates the app in airplane mode. During the night, the phone’s sensors—accelerometer, gyroscope, and microphone—capture respiratory movements, heartbeats, and sounds of breathing. 

The collected data points are analyzed by artificial intelligence, delivering 90% accuracy in categorizing affected individuals compared to standard clinical tests like polysomnography. Results are then made available to healthcare professionals through a dedicated dashboard, streamlining the diagnostic process and enhancing patient care.

The app uses the smartphone’s microphone and sensors, such as the accelerometer and gyroscope, capturing up to 3,000 data points per second. These tools record intricate respiratory and positional changes across six axes, which are analyzed by AI to deliver clinical-grade results.

Severin Benizri, CEO and co-founder of APNEAL, explained, “Our goal is to radically simplify the diagnostic journey for sleep apnea. By leveraging advanced smartphone sensors and artificial intelligence, we’re making this crucial step accessible to everyone, with reliability comparable to dedicated sleep examination hardware.”

APNEAL has already demonstrated its efficacy in a preliminary study at Bichat Hospital with 50 patients, achieving 90% accuracy in categorizing affected individuals. A study is currently being conducted for device validation and involves 1,000 patients in 20 European centers in France, Germany, and Spain. 

This study will enable CE marking and FDA approval by 2025, with full-scale deployment planned for 2026. Real-life and health economics studies with pharmacies, insurance companies, and clinical research organizations will begin in early 2025.

APNEAL will showcase live demos at Venetian Expo, Hall G – 60601 at Eureka Park.

Keep Up With Our Content. Subscribe To Medical Product Outsourcing Newsletters